Jul. 5 at 5:17 PM
$ABCL
$ABCL
🔥 Why
$20 Isn’t a Dream – It’s a Setup 🔥
When ~77% of the float is locked in strong hands (insiders + institutions + shorts), there’s barely any room for sellers. Add a few positive catalysts – milestone payments, new AI-driven partnerships, or FDA fast-track approvals – and the price action won’t just climb… it could launch.
The technicals are already screaming bullish: golden crosses, breakout formations, and volume patterns showing accumulation. The first targets are
$7–10, but if momentum builds and shorts scramble to cover,
$15–20 becomes a logical endgame.
Remember: AbCellera IPO’d at
$20 when all it had was promise. Now it has
$800M+ cash, a GMP facility coming online, and a growing clinical pipeline. The fundamentals are stronger than ever.
😏 Are you really betting this won’t return to IPO levels?
